Hong-feng Chen

Hong-feng Chen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in Translational Oncology
Verified
Journal Article
Open access
MCMeiling Chu
Meiling Chu
YZYan Zhang
Yan Zhang
MYMeina Ye
Meina Ye
YYYu-lian Yin
Yu-lian Yin
HCHong-feng Chen
Hong-feng Chen
Aromatase inhibitors (AIs) are the main drugs used in the endocrine therapy of breast cancer. Given the continuous reduction in their estrogen levels, the quality of life and medication compliance of patients with osteopenia and osteoporosis, also called aromatase inhibitor-associated bone loss (AIBL), are seriously affected. Yi Shen Tiao Gan decoction (YSTG) is a traditional Chinese medicine prescription that is widely used in China to treat AIBL. Clinical studies have shown that YSTG can effectively decelerate AIBL. However, the molecular mechanisms underlying the effects of YSTG on AIBL remain unclear. In contrast to previous studies on the mechanism of AIBL, which focused on the relationship between estrogen and osteoclasts, this study adopts a novel perspective by focusing on H-type blood vessels and Slit guidance ligand 3 (SLIT3). H-type vessels, a recently identified subtype of capillaries, are predominantly located in the epiphysis and endosteum of long bones. These vessels play a crucial role in mediating the coupling of angiogenesis and osteogenesis within the bone microenvironment, with their abundance serving as a sensitive indicator of bone mass. Notably, SLIT3, a proangiogenic factor secreted by osteoblasts, is actively involved in the regulation of H-type vessel formation and bone formation processes. Here, we used the inoculation and resection of breast cancer xenografts, bilateral ovaritectomy (OVX), and gavage of letrozole (Femara) to construct a suitable AIBL animal model, which was verified by ELISA, microcomputed tomography (micro-CT), hematoxylin and eosin staining, and OCN and tartrate-resistant acid phosphatase (TRAP) immunohistochemical staining. H-type vessels were used as the entry point to study the mechanism of AIBL on the basis of the AIBL animal model. Among mice, the nude mice in the mastectomy (MX)+OVX+Le group showed the most severe bone loss after breast cancer cell implantation and resection, OVX, and Le gavage. Therefore, this group was suitable as an animal model of breast cancer AIBL than other groups. The animal experiment on the mechanism of YSTG in improving bone loss found that YSTG treatment significantly reduced the contents of C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide, and growth hormone and increased those of serum estradiol and SLIT3. Micro-CT quantitative detection showed that after YSTG treatment, bone BMD, BV:TV, and Tb.N increased. The HE staining of bone tissue revealed that the thickness and number of trabecular bone and the number of cells in the cartilage layer of the femur remarkably increased after YSTG treatment. YSTG reduced TRAP content near the growth plate of the femoral metaphysis. YSTG significantly increased the OCN content at the margin of the trabecular bone in the metaphysis of the femur. Immunofluorescence results confirmed that YSTG could increase the amount of H-type vascular cells in bone. WB analysis confirmed that YSTG could significantly up-regulate the expression of SLIT3 protein in bone tissue. Therefore, YSTG may improve bone loss by up-regulating SLIT3 to induce H-type angiogenesis.

25 July 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYan Zhang
Yan Zhang
MCMeiling Chu
Meiling Chu
MYMeina Ye
Meina Ye
YCYiqin Cheng
Yiqin Cheng
HCHui Cong
Hui Cong
HCHong-feng Chen
Hong-feng Chen
Background: Aromatase inhibitor-induced musculoskeletal syndrome (AIMSS) has emerged as a major cause of treatment discontinuation in hormone receptor-positive patients treated with aromatase inhibitors. There are currently no standardized guidelines or universally accepted treatments for AIMSS. Therefore, this exploratory study aimed to preliminarily evaluate the efficacy and safety of Yi Shen Tiao Gan formula in AIMSS patients.Methods: A total of 136 patients with AIMSS were included in this single-center, randomized, controlled, single-blind trial and were randomised into the treatment and control groups at a ratio of 1:1. All patients were routinely given Caltrate D. Patients in the treatment group took Breast surgery formula combined with Yi Shen Tiao Gan formula and control group took Breast surgery formula twice a day. The treatment period of Chinese medicine was 3 months as one course of treatment. The clinical efficacy of two courses of treatment was observed in this study. The study observed and compared the following indicators between the two groups: the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, Traditional Chinese Medicine symptom and sign scores, bone mineral density, bone metabolism biochemical indicators, bone metabolism-related hormones and safety assessments.Results: In total, 108 participants were included in the analysis. Before and after treatment, the total WOMAC score of both groups of patients significantly decreased (p < 0.05), with the pain subscale score of the treatment group being significantly lower than that of the control group (p < 0.05). The TCM symptom and sign score significantly decreased in both groups (p < 0.05), with a more pronounced reduction in the treatment group (p < 0.05). The bone mineral density T-score of both groups of patients showed a downward trend. The decrease in the left femoral bone density T-score was smaller in the treatment group, while the decline in the lumbar spine bone density T-score was slower in the control group. There was no significant difference in bone metabolism levels between the two groups (p > 0.05), but the decrease in β-CTX was slightly slower in the treatment group of the AI + OFS population compared to the control group. After applying Bonferroni correction for multiple testing, these associations did not reach statistical significance. No serious adverse events were observed in either group.Conclusion: The YSTG formula significantly reduced WOMAC scores, improving pain, stiffness, physical function in patients with AIMSS, and alleviating the traditional Chinese medicine symptoms and signs of liver and kidney deficiency, thereby enhancing the overall quality of life for patients.Clinical Trial Registration: http://www.chictr.org.cn, identifer ChiCTR2200057785.

23 January 2023 in Research Square
Verified
Preprint
Open access
PDF file
YYYulian Yin
Yulian Yin
HLHaoxin Le
Haoxin Le
YCYifan Cheng
Yifan Cheng
YZYuanyuan Zhong
Yuanyuan Zhong
YCYiqin Cheng
Yiqin Cheng
HCHong-feng Chen
Hong-feng Chen
Background Non-puerperal mastitis (NPM) is an umbrella term for non-specific inflammatory mastitis inflammation with unclear etiology. The objective of the current study is to characterize NPM patients and examine the determinants associated with NPM severity. Methods This study analyzed the NPM inpatients admitted to the Department of Breast Surgery, Longhua Hospital Affiliated with Shanghai University of Traditional Chinese Medicine from 2016 to 2020. We explored NPM patient characteristics through demographics, physical risks, lab tests, and medical history indicators. Multivariable logistic regression was conducted to identify the relationship between the prolactin (PRL) level and NPM severity stratified by breast structure. Findings The majority of NPM inpatients had normal breast structures and were of lower average age than those with congenital nipple deformity (p=0.002). Significant positive risk (p< 0.001) association between PRL level and NPM severity was observed among NPM inpatients with normal breast structure in both binomial (OR: 2.91; 95%CI:1.88-4.52) and ordinal regression model (OR: 3.47; 95%CI:2.39-5.08), with age as a protective factor (OR:0.94; 95%CI:0.91-0.97). For NPM patients with nipple deformity, increasing odds of NPM severity regarding higher PRL level was only observed in ordinal logistic regression, which was lower (OR: 2.21; 95%CI: 1.14-4.34; p=0.02) than their peer with normal breast structure. Interpretation The risk of NPM severe episodes is higher among patients with higher PRL levels, of which the association is stronger for NPM patients with normal breast structure, implying different pathogenesis between NPM patients with varied breast anatomy. Testification of the analysis model indicates an improvement window for the current NPM severity assessment. Funding This study was supported by the second major clinical research project of "Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals (2020-2022)" (SHDC2020CR2051B), the National Natural Science Foundation of China (No.82104854), and Shanghai Sailing Program (20YF1449800).